2023
Adherence to Tumor Board Recommendations in the Treatment of Patients with Hepatocellular Carcinoma
Cao Y, Mezzacappa C, Jaffe A, Strazzabosco M, Taddei T. Adherence to Tumor Board Recommendations in the Treatment of Patients with Hepatocellular Carcinoma. Journal Of Multidisciplinary Healthcare 2023, 16: 1531-1540. PMID: 37283950, PMCID: PMC10239642, DOI: 10.2147/jmdh.s407908.Peer-Reviewed Original ResearchMultidisciplinary liver tumor boardBarcelona Clinic Liver CancerHepatocellular carcinomaBCLC stageLocoregional therapyTreatment-naïve hepatocellular carcinomaTreatment of HCCTumor board recommendationsRetrospective cohort studyTertiary care centerChronic liver diseaseMultivariate Cox regressionKaplan-Meier analysisManagement of patientsTreatment of patientsUnifocal hepatocellular carcinomaCases of discordanceBCLC guidelinesPalliative intentTreatment discordanceUnifocal diseaseChart reviewCohort studyCurative therapyCurative treatment
2021
Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis
John BV, Schwartz K, Levy C, Dahman B, Deng Y, Martin P, Taddei TH, Kaplan DE. Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis. Hepatology Communications 2021, 5: 1426-1436. PMID: 34430786, PMCID: PMC8369937, DOI: 10.1002/hep4.1720.Peer-Reviewed Original ResearchPrimary biliary cholangitisLiver-related mortalityHepatic decompensationOCA useOCA usersPBC cirrhosisObeticholic acidPropensity score modelBiliary cholangitisScore modelRetrospective cohort studySerious liver injuryTreatment of patientsEffect of treatmentCohort studyPartial respondersLiver injuryMultivariable analysisPotential confoundersC-statisticUS veteransUrsodeoxycholic acidBaseline riskCirrhosisDecompensation